Details of the Drug

General Information of Drug (ID: DMFJTDI)

Drug Name

Sibutramine

Synonyms

Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Approved	[1], [2]

Therapeutic Class

Appetite Depressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

279.8

Topological Polar Surface Area (xlogp)

5.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The apparent oral clearance of drug is 1750 L/h [4]
Elimination: 0% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.1 hours [5]
Metabolism: The drug is metabolized via the hepatic [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7657 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 2.9 mg/mL [3]

Chemical Identifiers

Formula: C17H26ClN
IUPAC Name: 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
Canonical SMILES: CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
InChI: InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
InChIKey: UNAANXDKBXWMLN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5210
ChEBI ID: CHEBI:9137
CAS Number: 106650-56-0
DrugBank ID: DB01105
TTD ID: D08KVZ
VARIDT ID: DR00566
INTEDE ID: DR1479
ACDINA ID: D00400

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Modulator	[8]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Obesity

ICD Disease Classification

5B81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sibutramine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Sibutramine and Lorcaserin.	Obesity [5B80-5B81]	[29]
Propylhexedrine	DMTBW2O	Moderate	Additive hypertensive effects by the combination of Sibutramine and Propylhexedrine.	Obesity [5B80-5B81]	[30]
-----------

Coadministration of a Drug Treating the Disease Different from Sibutramine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Sibutramine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[31]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Sibutramine and Oliceridine.	Acute pain [MG31]	[32]
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Sibutramine and Inotersen.	Amyloidosis [5D00]	[33]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Sibutramine and Cilostazol.	Arterial occlusive disease [BD40]	[33]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Sibutramine and Levalbuterol.	Asthma [CA23]	[30]
Pirbuterol	DMI5678	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Pirbuterol.	Asthma [CA23]	[30]
Ephedrine	DMMV0KW	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Ephedrine.	Asthma [CA23]	[30]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Sibutramine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[34]
Dalfopristin	DM4LTKV	Minor	Decreased metabolism of Sibutramine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[30]
Clarithromycin	DM4M1SG	Minor	Decreased metabolism of Sibutramine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Sibutramine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[30]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Sibutramine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[36]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Sibutramine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Sibutramine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Sibutramine and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[38]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Sibutramine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Vilanterol	DMF5EK1	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Indacaterol	DMQJHR7	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Arformoterol	DMYM974	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Sibutramine and Dihydrocodeine.	Chronic pain [MG30]	[39]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Sibutramine and Levomilnacipran.	Chronic pain [MG30]	[34]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Sibutramine and Anisindione.	Coagulation defect [3B10]	[38]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Sibutramine and Regorafenib.	Colorectal cancer [2B91]	[33]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Sibutramine and Ardeparin.	Coronary thrombosis [BA43]	[33]
Osilodrostat	DMIJC9X	Minor	Decreased metabolism of Sibutramine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[30]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Sibutramine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[35]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Sibutramine and Danaparoid.	Deep vein thrombosis [BD71]	[40]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Sibutramine and Rivaroxaban.	Deep vein thrombosis [BD71]	[33]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Sibutramine and Vilazodone.	Depression [6A70-6A7Z]	[34]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Sibutramine and Vortioxetine.	Depression [6A70-6A7Z]	[34]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Sibutramine and Isocarboxazid.	Depression [6A70-6A7Z]	[41]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Sibutramine and Milnacipran.	Depression [6A70-6A7Z]	[34]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Sibutramine and Escitalopram.	Depression [6A70-6A7Z]	[34]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Sibutramine and Desvenlafaxine.	Depression [6A70-6A7Z]	[34]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Sibutramine and Clomipramine.	Depression [6A70-6A7Z]	[34]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Sibutramine and Doxepin.	Depression [6A70-6A7Z]	[34]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Sibutramine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[29]
LEVONORDEFRIN	DMWDJ0H	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and LEVONORDEFRIN.	Discovery agent [N.A.]	[30]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Sibutramine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Mephentermine	DMFJH5Q	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Mephentermine.	Essential hypertension [BA00]	[30]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Sibutramine and Tazemetostat.	Follicular lymphoma [2A80]	[38]
Itraconazole	DMCR1MV	Minor	Decreased metabolism of Sibutramine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Miconazole	DMPMYE8	Minor	Decreased metabolism of Sibutramine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Sibutramine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[38]
Dichlorphenamide	DMH7IDQ	Moderate	Increased risk of hyponatremia by the combination of Sibutramine and Dichlorphenamide.	Glaucoma [9C61]	[43]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Sibutramine and Sulfinpyrazone.	Gout [FA25]	[38]
Tetrahydrozoline	DMT57WC	Moderate	Additive hypertensive effects by the combination of Sibutramine and Tetrahydrozoline.	Herpes simplex infection [1F00]	[30]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Sibutramine and Procarbazine.	Hodgkin lymphoma [2B30]	[41]
Saquinavir	DMG814N	Minor	Decreased metabolism of Sibutramine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Sibutramine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Darunavir	DMN3GCH	Minor	Decreased metabolism of Sibutramine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Berotralstat	DMWA2DZ	Minor	Decreased metabolism of Sibutramine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[30]
Naphazoline	DMJFZDL	Moderate	Additive hypertensive effects by the combination of Sibutramine and Naphazoline.	Itching [1F28-1G07]	[30]
Ceritinib	DMB920Z	Minor	Decreased metabolism of Sibutramine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Sibutramine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[45]
Selpercatinib	DMZR15V	Minor	Decreased metabolism of Sibutramine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[30]
Idelalisib	DM602WT	Minor	Decreased metabolism of Sibutramine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[35]
IPI-145	DMWA24P	Minor	Decreased metabolism of Sibutramine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[30]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Sibutramine and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[33]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Sibutramine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[33]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Sibutramine and Ponatinib.	Mature B-cell lymphoma [2A85]	[33]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Sibutramine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[46]
Danazol	DML8KTN	Minor	Decreased metabolism of Sibutramine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[35]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Sibutramine and Lasmiditan.	Migraine [8A80]	[34]
Exjade	DMHPRWG	Moderate	Increased risk of bleeding by the combination of Sibutramine and Exjade.	Mineral absorption/transport disorder [5C64]	[33]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Sibutramine and Flibanserin.	Mood disorder [6A60-6E23]	[47]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Sibutramine and Ozanimod.	Multiple sclerosis [8A40]	[41]
Fedratinib	DM4ZBK6	Moderate	Increased risk of bleeding by the combination of Sibutramine and Fedratinib.	Myeloproliferative neoplasm [2A20]	[35]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Sibutramine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[48]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Sibutramine and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[33]
Dasatinib	DMJV2EK	Moderate	Increased risk of bleeding by the combination of Sibutramine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[33]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Sibutramine and Prasugrel.	Myocardial infarction [BA41-BA43]	[33]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Sibutramine and Vorapaxar.	Myocardial infarction [BA41-BA43]	[33]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Sibutramine and Bupropion.	Nicotine use disorder [6C4A]	[49]
Entrectinib	DMMPTLH	Minor	Decreased metabolism of Sibutramine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[30]
Polythiazide	DMCH80F	Moderate	Increased risk of hyponatremia by the combination of Sibutramine and Polythiazide.	Oedema [MG29]	[43]
Urea	DMUK75B	Moderate	Increased risk of hyponatremia by the combination of Sibutramine and Urea.	Oesophagitis [DA24]	[43]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Sibutramine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[32]
Rucaparib	DM9PVX8	Minor	Decreased metabolism of Sibutramine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[35]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Sibutramine and Oxymorphone.	Pain [MG30-MG3Z]	[32]
Dezocine	DMJDB0Y	Moderate	Additive serotonergic effects by the combination of Sibutramine and Dezocine.	Pain [MG30-MG3Z]	[32]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Sibutramine and Safinamide.	Parkinsonism [8A00]	[41]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Sibutramine and Rasagiline.	Parkinsonism [8A00]	[41]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Sibutramine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[50]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Sibutramine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[51]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Sibutramine and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[38]
Lonafarnib	DMGM2Z6	Minor	Decreased metabolism of Sibutramine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[30]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Sibutramine and Epoprostenol.	Pulmonary hypertension [BB01]	[33]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Sibutramine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[52]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Sibutramine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[30]
Larotrectinib	DM26CQR	Minor	Decreased metabolism of Sibutramine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[30]
LEE011	DMMX75K	Minor	Decreased metabolism of Sibutramine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Sibutramine and Plicamycin.	Testicular cancer [2C80]	[38]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Sibutramine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[53]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Sibutramine and Caplacizumab.	Thrombocytopenia [3B64]	[33]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Sibutramine and Apixaban.	Thrombosis [DB61-GB90]	[33]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Sibutramine and Cangrelor.	Thrombosis [DB61-GB90]	[38]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Sibutramine and Brilinta.	Thrombosis [DB61-GB90]	[33]
Cabozantinib	DMIYDT4	Moderate	Increased risk of bleeding by the combination of Sibutramine and Cabozantinib.	Thyroid cancer [2D10]	[33]
Xylometazoline	DMKV32D	Moderate	Increased risk of rapid heart rate by the combination of Sibutramine and Xylometazoline.	Vasomotor/allergic rhinitis [CA08]	[30]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Sibutramine and Betrixaban.	Venous thromboembolism [BD72]	[38]
-----------


⏷ Show the Full List of 101 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sibutramine 5 mg capsule	5 mg	Oral Capsule	Oral
Sibutramine 10 mg capsule	10 mg	Oral Capsule	Oral
Sibutramine 15 mg capsule	15 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2586).
2	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
3	BDDCS applied to over 900 drugs
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
20	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
21	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
22	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
23	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
24	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
25	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
26	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
27	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
28	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
29	Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4. [PMID: 11176649]
30	Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
31	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
32	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
33	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
34	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
35	Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
36	Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
37	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
38	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
39	Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5. [PMID: 18171260]
40	Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8. [PMID: 8826562]
41	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
42	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
43	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
44	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
45	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
47	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
48	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
50	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
51	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
52	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
53	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.